About Patient Decision Aids+
Purpose of patient decision aids
Patient decision aids encourage patient participation in treatment decision-making with their physician. This shared decision-making process can improve patient-physician communication and patient-focused care.
Patient decision aids:
- inform patients of their treatment options
- elicit patient values and preferences related to treatment
- improve patient knowledge and reduce decisional conflict. (Stacey et al., Cochrane Library, 2017)
Development of the InforMED decision aids
Decision aid content is derived from evidence-based clinical practice guidelines and primary research (see references) and reviewed by independent experts. The content will be updated based on new evidence-based guidelines. Patients and health care professionals are consulted on content, format, and use of the decision aids. This feedback informs further development. Developed decision aids are tested for effectiveness on increasing patient knowledge and reducing decisional conflict. They are appraised against the International Patient Decision Aids Standards.
Preparing to use a decision aid with patients
- Explore the decision aid. Understand how it informs patients of treatment options and encourages consideration of preferences and values.
- Familiarize yourself with the Patient Summary Page at the end of each decision aid. Patients may use the decision aid and print this summary to bring to a consultation.
- We suggest recommending these decision aids to patients to read on their own time. This may be most appropriate before or after the initial appointment, depending on your practice. These decision aids are comprehensive and may take patients some time to go through.
- More resources on shared decision making, including training, are available on the Ottawa Hospital Research Institute Website: https://decisionaid.ohri.ca/training.html
About the developers
The acne and psoriasis decision aids are developed by Windsor Clinical Research Inc. Consultation is provided by Dr. Jerry Tan (MD, FRCPC) at Windsor Clinical Research Inc., Western University, and the University of Windsor; and Dr. Robert Dellavalle (MD, PhD, MSPH) at University of Colorado Schools of Medicine and Public Health and US Department of Veterans Affairs. Support for the development of these decision aids was provided by a Pfizer Independent Grant for Learning and Change with the American Academy of Dermatology, a Valeant unrestricted educational grant, and Abbvie Innovation training.
The hidradenitis suppurativa decision aid is developed by Donna McLean, Olivia McBride, Dr. Jerry Tan, and Tanja Samardzic of Windsor Clinical Research Inc. Consultation is provided by Dr. Jerry Tan (MD, FRCPC) of Windsor Clinical Research Inc., Western University, and the University of Windsor; and Dr. Robert Dellavalle (MD, PhD, MSPH) of the University of Colorado Schools of Medicine and Public Health and US Department of Veterans Affairs. Consultation during the development of the decision aid was provided by Dr. Christopher Sayed (MD) of the University of North Carolina Hospital; Dr. Barry Resnik (MD) of the University of Miami School of Medicine, Provider Network Solutions, and Specialty Telehealth Solutions; Christine Yannuzzi of Hidradenitis Suppurativa Warriors; and Sandra Guilbault of Hope for HS and the Hidradenitis Suppurativa Foundation, Inc. Support for the development of the hidradenitis suppurativa decision aid was provided by an Advancing Science Through Pfizer-Investigator Research Exchange (ASPIRE) Grant.
Windsor Clinical Research Inc.
Dr. Jerry Tan and Windsor Clinical Research Inc. have a history of excellence in dermatology research and practice. Dr. Tan has written and advised on numerous clinical dermatology guidelines and independent studies, with an emphasis on quality of life of patients with skin diseases. Windsor Clinical Research Inc. has been producing patient decision aids since 2011, details of which can be found here.
Conflict of Interest
Acne and psoriasis decision aids
Dr. Tan has been an advisor, clinical investigator, speaker, and/or received honoraria from Abbvie, Boehringer Ingelheim, Cipher, Dermira, Galderma, Novartis, Pfizer, Roche, Valeant, and Xenon. Dr. Dellavalle has received grants, research and clinical trial support from Pfizer; royalties from UpToDate; and editorial stipends from Journal of Investigative Dermatology and Journal of the American Academy of Dermatology. All other authors report no conflicts of interest.
Hidradenitis suppurativa decision aid
Dr. Tan has been a speaker and consultant for, and/or received honoraria, grants, and research support from Almirall, Bausch, Boots/Walgreens, Botanix, Cipher, Galderma, Novan, Novartis, Pfizer, Promius, Sun, and Vichy. Dr. Dellavalle has been an advisory board member of the Cochrane Council, received grants from Pfizer, and received honoraria from Brown University and Altus Labs. Dr. Sayed has been an advisory board member and speaker for, and/or received honoraria and grants from Abbvie, InflaRx, Novartis, and UCB. Dr. Resnik has been an advisory board member for Abbvie. Sandra Guilbault is the director of Hope for HS and a board member for the Hidradenitis Suppurativa Foundation, Inc. All other authors report no conflicts of interest. The treatment choices patients make after using the decision aids will have no influence on the authors or their respective affiliations.
Tan J, Dellavalle RP, Cameron M, Henderin C, Reed A, McLellan C, O’Neil AI, Boyal S. Development of Patient Decision Aids for Plaque Psoriasis and Acne. Oral presentation at: The 92nd Annual Conference of the Canadian Dermatology Association; 2017 June 21-24; Fredericton, Canada.
Tan J, Cameron M, McLellan C, O’Neil AI, Reed A, Henderin C, Dellavalle RP. Development of Patient Decision Aids for Plaque Psoriasis and Acne. Poster presentation at: The 9th International Shared Decision Making Conference; 2017 July 2-5; Lyon, France.